Table 1.
Large (>1.000 patients) retrospective cohort studies evaluating the effect of cytoreductive nephrectomy on overall survival in mRCC.
| Reference (year) | Participants (n) | Treatment arms (n) | Median age (years) | Poor PS (KPS > 80 or ECOG ≥ 2) | Poor patient risk category (IMDC or MSKCC) | Clinical stage T1 | mOS (months) |
|---|---|---|---|---|---|---|---|
| Hanna et al. (2016) (28) | 15,390 | CN (5374) | 60 | NR | NR | 29.5% | 32.5 |
| No CN (10,016) | 64 | NR | NR | 15.3% | 14.9 | ||
| Heng et al. (2014) (29) | 1658 | CN (982) | 60 | 19% | 28% | NR | 20.6 |
| No CN (676) | 59 | 42% | 54% | NR | 9.6 | ||
| Conti et al. (2014) (17) | 20,104 | CN (6915) | 61 | NR | NR | NR | 15 |
| No CN (13,189) | 68 | NR | NR | NR | 4 | ||
| Abern et al. (2014) (30) | 7143 | CN (2629) | 61 | NR | NR | 15% | NR |
| No CN (4514) | 68 | NR | NR | 19% | NR |
Statistically significant differences in bold.
NR, not reported; CN, cytoreductive nephrectomy; PS, performance status; MSKCC, Memorial Sloan Kettering Cancer Center; mOS, median overall survival; KPS, Karnofsky Performance Scale; ECOG, Eastern Cooperative Oncology Group; IMDC, International mRCC Database Consortium.